$16.90
+0.87 (+5.43%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IMUX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 3 with posted results
Held by 6 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, +1 more) · FINRA short interest 10.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441To evaluate efficacy of IMU-838 versus placebo regarding time to first relapseRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: IMU-838 tablets, Placebo matching IMU-838 tablets | Multiple Sclerosis | 1,121 | Nov 2026 | ≤ 103 d | 2026-02-23 |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638To evaluate efficacy of IMU-838 versus placebo based on time to first relapseRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: IMU-838 tablets, Placebo matching IMU-838 tablets | Multiple Sclerosis, Relapsing-Remitting | 1,100 | Nov 2026 | ≤ 103 d | 2026-02-23 |
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219results2021-07-23Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI LesionsRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo, IMU-838 (10 mg/day) | Relapsing-Remitting Multiple Sclerosis (RRMS) | 210 | 2020-04-24actual | — | 2024-04-24 |
| Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140Efficacy of IMU-838 versus placeboRandomized · Double-masked · Treatment | Phase 2 | Unknown status | Drug: IMU-838, Placebo matching IMU-838 | Multiple Sclerosis | 450 | 2025-01-07 | — | 2024-04-29 |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate CancerNCT05124795Incidence and the grade (severity) of dose-limiting toxicities (DLTs) within 28 days after start of study treatment to identify the MTD and the RP2DNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Lack of Efficacy | Drug: IMU-935 | Metastatic Castration Resistant Prostate Cancer | 18 | 2023-05-31actual | — | 2024-01-17 |
| Phase 2 Dose-finding IMU-838 for Ulcerative ColitisNCT03341962results2024-03-05Induction Phase: Symptomatic Remission and Endoscopic Healing at Week 10Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the OLE was prematurely closed by the sponsor. | Drug: IMU-838, Placebo | Ulcerative Colitis | 263 | 2022-11-16actual | — | 2024-03-05 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)NCT04379271results2024-11-13Proportion of Patients Without Any Need for INV Until EoSRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: IMU-838 · Other: Placebo | COVID-19 | 234 | 2021-01-12actual | — | 2024-11-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19